Cancer/Tumor Profiling Market by Technology (Immunoassay, NGS, PCR, In Situ Hybridization), Cancer Type (Breast, Lung, Colorectal), Biomarker Type (Genomic Biomarkers, Protein Biomarkers), Application (Diagnostics, Prognostics) - Global Forecast to 2024
[223 Pages Report] Cancer/Tumor profiling market is projected to reach USD 12.4 billion by 2024 from USD 7.5 billion in 2019, at a CAGR of 10.5%. Growth in this market is driven by the growing incidences of cancer across the globe and the increasing use of biomarkers in tumor profiling. Other market drivers include an increase in cancer research & funding and technological advancements in profiling technologies.
By technology, immunoassays dominated cancer/tumor profiling market in 2018
Based on technology, market has been segmented into immunoassays, in-situ hybridization, next-generation sequencing (NGS), polymerase chain reaction (PCR), mass spectrometry, microarrays, and other technologies. The immunoassays segment accounted for the largest market share in 2018 due to its use as a gold standard to conduct tumor profiling on a large scale as they help measure the presence and concentration of analytes in a sample. Moreover, the information gained by these tests in clinical settings helps shorten hospital stays and decrease the severity of illnesses by identifying & assessing the progression of the disease, leading to improved therapeutic choices.
Breast cancer accounted for the largest share of cancer/tumor profiling market in 2018
Based on cancer type, market has been segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, and other cancers. In 2018, the breast cancer segment accounted for the largest share of market. The high prevalence of breast cancer across the globe is the primary factor contributing to the large percentage of this segment.
Genetic biomarkers were the most widely used type within cancer/tumor profiling market in 2018
Based on biomarker type, market is segmented into genetic biomarkers, protein biomarkers, and other biomarkers. In 2018, the genetic biomarkers segment accounted for the largest share of market. The large share of this segment can be attributed to the high adoption of these biomarkers during cancer diagnosis and prognosis and in the biomarker discovery process.
Research was the largest application of cancer/tumor profiling market in 2018
Based on applications, market is segmented into research and clinical applications. The research applications segment accounted for the largest share of market in 2018. The large share of this segment is attributed to the increasing focus on biomarker discovery for drug development along with the rapidly growing field of personalized medicine. Additionally, the growing funding for cancer research is propelling the growth of the market.
The APAC market is expected to grow at the highest CAGR during the forecast period
Cancer/tumor profiling market in the Asia Pacific is expected to grow at the highest CAGR during the forecast period. The high incidence of cancer, increasing proteomics & genomics research, growing research funding, rising investments by pharmaceutical & biotechnology companies, and awareness about personalized therapeutics in the region are propelling the market growth.
Key Market Players
The prominent players in this market are Illumina, Inc. (US), QIAGEN N.V. (Germany), NeoGenomics Laboratories, Inc. (US), HTG Molecular Diagnostics, Inc. (US), Genomic Health Inc. (US), Caris Life Sciences (US), Helomics Corporation (US), NanoString Technologies, Inc. (US), Sysmex Corporation (Japan), RiboMed Biotechnologies, Inc. (US), Guardant Health, Inc. (US), and Foundation Medicine (US).
Illumina (US) is a global manufacturer of sequencing- & array-based solutions for genetic & genomic analysis and holds a leading position in market. Owing to its strong sales and distribution network, the company has a significant global footprint. The company leverages the advantage of an established brand name in the market. The company strategically concentrates on developing core technologies, assay chemistries, systems, and software to expedite the collection, analysis, and application of biological information. For this purpose, the company primarily pursues the strategies of collaborations and agreements. With a strong global presence, Illumina is continuously involved in product and technological innovations for market, which has led to an increase in the companys overall revenue. It focuses on acquiring new consumers through expansions, partnerships, and collaborations, along with introducing advanced products in the market.
Scope of the Report:
|
Report Metric |
Details |
|
Market size available for years |
20172024 |
|
Base year considered |
2018 |
|
Forecast period |
20192024 |
|
Forecast units |
Value (USD) |
|
Segments covered |
Technology, Cancer Type, Biomarker Type, Application, and Region |
|
Geographies covered |
North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa |
|
Companies covered |
Illumina, Inc. (US), QIAGEN N.V. (Germany), NeoGenomics Laboratories, Inc. (US), HTG Molecular Diagnostics, Inc. (US), Genomic Health Inc. (US), Caris Life Sciences (US), Helomics Corporation (US), NanoString Technologies, Inc. (US), Sysmex Corporation (Japan), Ribomed Biotechnologies, Inc. (US), Guardant Health, Inc. (US), and Foundation Medicine (US). |
The research report categorizes the market into the following segments and subsegments:
Cancer/Tumor Profiling Market, by Technology
- Immunoassays
- Next Generation Sequencing (NGS)
- Polymerase Chain Reaction (PCR)
- In-Situ Hybridization (ISH)
- Microarrays
- Mass Spectrometry
- Others
Cancer/Tumor Profiling Market, by Cancer Type
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Melanoma
- Others Cancers
Cancer/Tumor Profiling Market, by Biomarker Type
- Genetic Biomarkers
- Protein Biomarkers
- Other Biomarkers
Cancer/Tumor Profiling Market, by Application
- Research
- Biomarker discovery
- Personalized Medicine
- Clinical
- Diagnostics
- Prognostics
- Screening
- Treatment & Monitoring
Cancer/Tumor Profiling Market, by Region
- North America
- US
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Rest of Asia Pacific
- Latin America
- Middle East & Africa
Recent Developments
- In May 2019, QIAGEN N.V. (Germany) launched its therascreen PIK3CA RGQ PCR Kit (therascreen PIK3CA Kit) as a companion diagnostic to aid in identifying breast cancer patients.
- In May 2019, NeoGenomics Laboratories collaborated with QIAGEN to offer companion diagnostic test for HR+/HER2 for advanced breast cancer patients to detect PIK3CA mutation using QIAGENs therascreen PIK3CA RGQ PCR test.
- In May 2018, Illumina acquired Edico Genome, a leading provider of data analysis acceleration solutions for NGS to accelerate genomic data analysis.
- In August 2018, HTG Molecular Diagnostics, Inc. (US) entered into an agreement with Oncologie, Inc. (US) under which the two companies will undertake the development of biomarkers associated with Oncologies Immuno-oncology pipeline.
Critical questions answered in the report:
- How will the current technological trends affect market in the long term?
- How is the biomarkers market for cancer/tumor profiling moving?
- What are the application areas of market?
- Which regions are likely to grow at the highest CAGR?
- What are the growth strategies being implemented by major market players?
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
Table of Contents
1 Introduction (Page No. - 19)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1.1 Markets Covered
1.3.1.2 Years Considered for the Study
1.4 Currency
1.5 Stakeholders
1.6 Limitations
2 Research Methodology (Page No. - 22)
2.1 Research Approach
2.1.1 Secondary Research
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Research
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Breakdown of Primaries
2.1.2.3 Key Industry Insights
2.2 Market Size Estimation
2.3 Data Triangulation Approach
2.4 Assumptions for the Study
3 Executive Summary (Page No. - 30)
4 Premium Insights (Page No. - 35)
4.1 Cancer/Tumor Profiling: Market Overview
4.2 Market: Geographic Growth Opportunities
4.3 Regional Mix: Market (20192024)
4.4 Market: Developed vs Developing Markets (2019 vs 2024)
5 Market Overview (Page No. - 39)
5.1 Introduction
5.2 Market Dynamics
5.2.1 Market Drivers
5.2.1.1 Increasing Incidence of Cancer
5.2.1.2 Increasing Use of Biomarkers in Cancer Profiling
5.2.1.3 Increasing Cancer Research and Funding
5.2.1.4 Technological Advancements
5.2.2 Market Restraints
5.2.2.1 High Capital Investment
5.2.2.2 Technical Issues With Sample Collection and Storage
5.2.3 Market Opportunities
5.2.3.1 Increasing Demand for Personalized Medicine
5.2.3.2 Growing Need for Point-Of-Care Diagnostics
5.2.4 Market Challenges
5.2.4.1 Low Biomarker Discovery-To-Approval Ratio
5.2.4.2 Poor Regulatory and Reimbursement Scenario
6 Industry Insights (Page No. - 48)
6.1 Introduction
6.2 Industry Trends
6.2.1 Integration of Omics Data
6.2.2 Advances in Liquid Biopsy
6.2.3 Organoids for Personalized Medicine
7 Cancer/Tumor Profiling Market, By Technology (Page No. - 51)
7.1 Introduction
7.2 Immunoassays
7.2.1 Immunoassay Tests Identify and Assess the Progression of Disease, Thereby Providing Information Vital for Better Therapeutic Choices
7.3 Next-Generation Sequencing
7.3.1 Advances in NGS Multiplexing Capabilities Enable One Assay to Provide A Complete Tumor Molecular Profile
7.4 Polymerase Chain Reaction
7.4.1 Real-Time PCR Helps in the Quantification of Low-Copy Transcripts, Aiding Biomarker Identification
7.5 In Situ Hybridization
7.5.1 Fish is the Gold Standard for Evaluating Some Key Biomarkers and Plays A Critical Role in Guiding Targeted Therapies
7.6 Microarrays
7.6.1 Microarrays are Widely Adopted in Diagnostics as They AID in Predicting the Recurrence of Cancer After Treatment
7.7 Mass Spectrometry
7.7.1 Technological Advancements are Supporting the Adoption of This Technology for Sensitive, Reliable, and Rapid Diagnosis
7.8 Other Technologies
8 Cancer/Tumor Profiling Market, By Cancer Type (Page No. - 65)
8.1 Introduction
8.2 Breast Cancer
8.2.1 Breast Cancer is the Most Common Cancer Found Among Women
8.3 Lung Cancer
8.3.1 Molecular Characterization of Tumors Using NGS has is A Key Tool for the Clinical Management of Nsclc Patients
8.4 Colorectal Cancer
8.4.1 IHC, PCR, Microarrays, and Imaging Technologies are Major Technologies Used in Colorectal Diagnostics
8.5 Prostate Cancer
8.5.1 Prostate-Specific Antigen is A Widely Used Fda-Approved Biomarker for Prostate Cancer Screening
8.6 Melanoma
8.6.1 RT-QPCR is Generally Utilized to Conduct Molecular Profiling and Analyze Biomarkers in Melanomas
8.7 Other Cancers
9 Cancer/Tumor Profiling Market, By Biomarker Type (Page No. - 77)
9.1 Introduction
9.2 Genetic Biomarkers
9.2.1 Genetic Biomarkers are Frequently Used in Clinical Practice for Diagnosis and Prognosis
9.3 Protein Biomarkers
9.3.1 Proteomic Methods Showcase Significant Promise for the Discovery of Novel Biomarkers
9.4 Other Biomarkers
10 Cancer/Tumor Profiling Market, By Application (Page No. - 84)
10.1 Introduction
10.2 Research Applications
10.2.1 Biomarker Discovery
10.2.1.1 Biomarkers are Being Exploited for the Development of Personalized Or Precision Medicine
10.2.2 Personalized Medicine
10.2.2.1 The Field of Personalized Medicine is Witnessing Rapid Growth in the Area of Oncology
10.3 Clinical Applications
10.3.1 Diagnostics
10.3.1.1 Tumor Profiling is Rapidly Gaining Momentum in the Area of Diagnostics
10.3.2 Prognostics
10.3.2.1 Advancements in Molecular Biology are Aiding the Uptake of Tumor Profiling in This Segment
10.3.3 Monitoring & Treatment
10.3.3.1 Multiplatform Profiling Analyses are Gaining Recognition for Monitoring and Treatment Among Cancer Patients
10.3.4 Screening
10.3.4.1 Screening Tests Help in Deciding If Diagnostic Tests are Required By the Patient
11 Cancer/Tumor Profiling Market, By Region (Page No. - 95)
11.1 Introduction
11.2 North America
11.2.1 US
11.2.1.1 US Dominates the North American Market
11.2.2 Canada
11.2.2.1 Growing Public-Private Partnerships to Promote Proteomics Research are Expected to Drive the Market in Canada
11.3 Europe
11.3.1 Germany
11.3.1.1 Advancements Proteomics and Genomics Research are Expected to Drive Market Growth
11.3.2 UK
11.3.2.1 Growth in the Life Science Industry and the Increase in Academia-Industry Partnerships Will Be the Key Factors Driving the Market
11.3.3 France
11.3.3.1 Growth in This Market is Primarily Driven By Increasing Investments in Life Science R&D for Infrastructural Development
11.3.4 Italy
11.3.4.1 Increasing Investment in Cancer and Translational Research is Expected to Propel Market Growth During the Forecast Period
11.3.5 Spain
11.3.5.1 Rising Incidence of Cancer and Increasing Focus on Cancer Biomarkers By Various Medical Societies to Support Market Growth in Spain
11.3.6 Rest of Europe
11.4 Asia Pacific
11.4.1 Japan
11.4.1.1 Large Number of Research Initiatives Towards the Development of Precision Medicine Supporting Market Growth in Japan
11.4.2 China
11.4.2.1 China has the Fastest-Growing Research Sector in the APAC Region
11.4.3 India
11.4.3.1 Increasing Pharma R&D and Government Funding in the Biotechnology Industry are the Major Factors Driving Market Growth in India
11.4.4 Rest of Asia Pacific
11.5 Latin America
11.5.1 Growing Proteomics Research in the Field of Cancer Along With the Rising Use of Advanced Techniques to Drive Market Growth
11.6 Middle East & Africa
11.6.1 Growing Genomics and Proteomics Research and Increasing Research Collaborations are Expected to Support Market Growth
12 Competitive Landscape (Page No. - 155)
12.1 Overview
12.2 Competitive Leadership Mapping
12.2.1 Visionary Leaders
12.2.2 Innovators
12.2.3 Dynamic Differentiators
12.2.4 Emerging Companies
12.3 Competitive Situation and Trends
12.3.1 Product Launches, Approvals, and Enhancements
12.3.2 Expansions
12.3.3 Acquisitions
12.3.4 Other Strategies
13 Company Profiles (Page No. - 162)
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*
13.1 Illumina, Inc.
13.2 Qiagen N.V.
13.3 Neogenomic Laboratories, Inc.
13.4 Sysmex Corporation
13.5 HTG Molecular Diagnostics, Inc.
13.6 Helomics Corporation
13.7 Genomic Health, Inc.
13.8 Caris Life Sciences
13.9 Nanostring Technologies, Inc.
13.10 Ribomed Biotechnologies, Inc.
13.11 Guardant Health, Inc.
13.12 Foundation Medicine
*Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View Might Not Be Captured in Case of Unlisted Companies
14 Appendix (Page No. - 213)
14.1 Insights of Industry Experts
14.2 Market Sizing & Validation Approach
14.3 Discussion Guide
14.4 Knowledge Store: Marketsandmarkets Subscription Portal
14.5 Available Customizations
14.6 Related Reports
14.7 Author Details
List of Tables (121 Tables)
Table 1 Market Drivers: Impact Analysis
Table 2 Market Restraints: Impact Analysis
Table 3 Market Opportunities: Impact Analysis
Table 4 Market Challenges: Impact Analysis
Table 5 Market, By Technology, 20172024 (USD Million)
Table 6 Market for Immunoassays, By Country, 20172024 (USD Million)
Table 7 Cancer/Tumor Profiling Market for Next-Generation Sequencing, By Country, 20172024 (USD Million)
Table 8 Market for Polymerase Chain Reaction, By Country, 20172024 (USD Million)
Table 9 Market for in Situ Hybridization, By Country, 20172024 (USD Million)
Table 10 Market for Microarrays, By Country, 20172024 (USD Million)
Table 11 Market for Mass Spectrometry, By Country, 20172024 (USD Million)
Table 12 Market for Other Technologies, By Country, 20172024 (USD Million)
Table 13 Market, By Cancer Type, 20172024 (USD Million)
Table 14 Market for Breast Cancer, By Country, 20172024 (USD Million)
Table 15 Market for Lung Cancer, By Country, 20172024 (USD Million)
Table 16 Market for Colorectal Cancer, By Country, 20172024 (USD Million)
Table 17 Market for Prostate Cancer, By Country, 20172024 (USD Million)
Table 18 Cancer/Tumor Profiling Market for Melanoma, By Country, 20172024 (USD Million)
Table 19 Market for Other Cancers, By Country, 20172024 (USD Million)
Table 20 Market, By Biomarker Type, 20172024 (USD Million)
Table 21 Market for Genetic Biomarkers, By Country, 20172024 (USD Million)
Table 22 Market for Protein Biomarkers, By Country, 20172024 (USD Million)
Table 23 Market for Other Biomarkers, By Country, 20172024 (USD Million)
Table 24 Market, By Application, 20172024 (USD Million)
Table 25 Market for Research Applications, By Type, 20172024 (USD Million)
Table 26 Market for Biomarker Discovery, By Country, 20172024 (USD Million)
Table 27 Market for Personalized Medicine, By Country, 20172024 (USD Million)
Table 28 Market for Clinical Applications, By Type, 20172024 (USD Million)
Table 29 Cancer/Tumor Profiling Market for Diagnostics, By Country, 20172024 (USD Million)
Table 30 Market for Prognostics, By Country, 20172024 (USD Million)
Table 31 Market for Monitoring & Treatment, By Country, 20172024 (USD Million)
Table 32 Market for Screening, By Country, 20172024 (USD Million)
Table 33 Market, By Region, 20172024 (USD Million)
Table 34 North America: Market, By Country, 20172024 (USD Million)
Table 35 North America: Market, By Technology, 20172024 (USD Million)
Table 36 North America: Market, By Cancer Type, 20172024 (USD Million)
Table 37 North America: Market, By Biomarker Type, 20172024 (USD Million)
Table 38 North America: Market for Research Applications, By Type, 20172024 (USD Million)
Table 39 North America: Market for Clinical Applications, By Type, 20172024 (USD Million)
Table 40 US: Cancer/Tumor Profiling Market, By Technology, 20172024 (USD Million)
Table 41 US: Market, By Cancer Type, 20172024 (USD Million)
Table 42 US: Market, By Biomarker Type, 20172024 (USD Million)
Table 43 US: Market for Research Applications, By Type, 20172024 (USD Million)
Table 44 US: Market for Clinical Applications, By Type, 20172024 (USD Million)
Table 45 Canada: Market, By Technology, 20172024 (USD Million)
Table 46 Canada: Market, By Cancer Type, 20172024 (USD Million)
Table 47 Canada: Market, By Biomarker Type, 20172024 (USD Million)
Table 48 Canada: Market for Research Applications, By Type, 20172024 (USD Million)
Table 49 Canada: Market for Clinical Applications, By Type, 20172024 (USD Million)
Table 50 Europe: Market, By Country, 20172024 (USD Million)
Table 51 Europe: Market, By Technology, 20172024 (USD Million)
Table 52 Europe: Market, By Cancer Type, 20172024 (USD Million)
Table 53 Europe: Market, By Biomarker Type, 20172024 (USD Million)
Table 54 Europe: Market for Research Applications, By Type, 20172024 (USD Million)
Table 55 Europe: Market for Clinical Applications, By Type, 20172024 (USD Million)
Table 56 Germany: Market, By Technology, 20172024 (USD Million)
Table 57 Germany: Market, By Cancer Type, 20172024 (USD Million)
Table 58 Germany: Market, By Biomarker Type, 20172024 (USD Million)
Table 59 Germany: Market for Research Applications, By Type, 20172024 (USD Million)
Table 60 Germany: Market for Clinical Applications, By Type, 20172024 (USD Million)
Table 61 UK: Market, By Technology, 20172024 (USD Million)
Table 62 UK: Cancer/Tumor Profiling Market, By Cancer Type, 20172024 (USD Million)
Table 63 UK: Market, By Biomarker Type, 20172024 (USD Million)
Table 64 UK: Market for Research Applications, By Type, 20172024 (USD Million)
Table 65 UK: Market for Clinical Applications, By Type, 20172024 (USD Million)
Table 66 France: Market, By Technology, 20172024 (USD Million)
Table 67 France: Market, By Cancer Type, 20172024 (USD Million)
Table 68 France: Market, By Biomarker Type, 20172024 (USD Million)
Table 69 France: Market for Research Applications, By Type, 20172024 (USD Million)
Table 70 France: Market for Clinical Applications, By Type, 20172024 (USD Million)
Table 71 Italy: Market, By Technology, 20172024 (USD Million)
Table 72 Italy: Market, By Cancer Type, 20172024 (USD Million)
Table 73 Italy: Market, By Biomarker Type, 20172024 (USD Million)
Table 74 Italy: Market for Research Applications, By Type, 20172024 (USD Million)
Table 75 Italy: Cancer/Tumor Profiling Market for Clinical Applications, By Type, 20172024 (USD Million)
Table 76 Spain: Market, By Technology, 20172024 (USD Million)
Table 77 Spain: Market, By Cancer Type, 20172024 (USD Million)
Table 78 Spain: Market, By Biomarker Type, 20172024 (USD Million)
Table 79 Spain: Market for Research Applications, By Type, 20172024 (USD Million)
Table 80 Spain: Market for Clinical Applications, By Type, 20172024 (USD Million)
Table 81 RoE: Market, By Technology, 20172024 (USD Million)
Table 82 RoE: Market, By Cancer Type, 20172024 (USD Million)
Table 83 RoE: Market, By Biomarker Type, 20172024 (USD Million)
Table 84 RoE: Market for Research Applications, By Type, 20172024 (USD Million)
Table 85 RoE: Cancer/Tumor Profiling Market for Clinical Applications, By Type, 20172024 (USD Million)
Table 86 Asia Pacific: Market, By Country, 20172024 (USD Million)
Table 87 Asia Pacific: Market, By Technology, 20172024 (USD Million)
Table 88 Asia Pacific: Market, By Cancer Type, 20172024 (USD Million)
Table 89 Asia Pacific: Market, By Biomarker Type, 20172024 (USD Million)
Table 90 Asia Pacific: Market for Research Applications, By Type, 20172024 (USD Million)
Table 91 Asia Pacific: Market for Clinical Applications, By Type, 20172024 (USD Million)
Table 92 Japan: Market, By Technology, 20172024 (USD Million)
Table 93 Japan: Cancer/Tumor Profiling Market, By Cancer Type, 20172024 (USD Million)
Table 94 Japan: Market, By Biomarker Type, 20172024 (USD Million)
Table 95 Japan: Market for Research Applications, By Type, 20172024 (USD Million)
Table 96 Japan: Market for Clinical Applications, By Type, 20172024 (USD Million)
Table 97 China: Market, By Technology, 20172024 (USD Million)
Table 98 China: Market, By Cancer Type, 20172024 (USD Million)
Table 99 China: Market, By Biomarker Type, 20172024 (USD Million)
Table 100 China: Cancer/Tumor Profiling Market for Research Applications, By Type, 20172024 (USD Million)
Table 101 China: Market for Clinical Applications, By Type, 20172024 (USD Million)
Table 102 India: Market, By Technology, 20172024 (USD Million)
Table 103 India: Market, By Cancer Type, 20172024 (USD Million)
Table 104 India: Market, By Biomarker Type, 20172024 (USD Million)
Table 105 India: Market for Research Applications, By Type, 20172024 (USD Million)
Table 106 India: Market for Clinical Applications, By Type, 20172024 (USD Million)
Table 107 RoAPAC: Market, By Technology, 20172024 (USD Million)
Table 108 RoAPAC: Market, By Cancer Type, 20172024 (USD Million)
Table 109 RoAPAC: Market, By Biomarker Type, 20172024 (USD Million)
Table 110 RoAPAC: Cancer/Tumor Profiling Market for Research Applications, By Type, 20172024 (USD Million)
Table 111 RoAPAC: Market for Clinical Applications, By Type, 20172024 (USD Million)
Table 112 Latin America: Market, By Technology, 20172024 (USD Million)
Table 113 Latin America: Market, By Cancer Type, 20172024 (USD Million)
Table 114 Latin America: Market, By Biomarker Type, 20172024 (USD Million)
Table 115 Latin America: Market for Research Applications, By Type, 20172024 (USD Million)
Table 116 Latin America: Market for Clinical Applications, By Type, 20172024 (USD Million)
Table 117 Middle East & Africa: Market, By Technology, 20172024 (USD Million)
Table 118 Middle East & Africa: Market, By Cancer Type, 20172024 (USD Million)
Table 119 Middle East & Africa: Cancer/Tumor Profiling Market, By Biomarker Type, 20172024 (USD Million)
Table 120 Middle East & Africa: Market for Research Applications, By Type, 20172024 (USD Million)
Table 121 Middle East & Africa: Market for Clinical Applications, By Type, 20172024 (USD Million)
List of Figures (38 Figures)
Figure 1 Cancer/Tumor Profiling Market
Figure 2 Research Design
Figure 3 Breakdown of Primary Interviews: By Company Type, Designations, and Region
Figure 4 Bottom-Up Approach
Figure 5 Top-Down Approach
Figure 6 Data Triangulation Methodology
Figure 7 Market, By Technology, 2019 vs 2024 (USD Million)
Figure 8 Market, By Cancer Type, 2019 vs 2024 (USD Million)
Figure 9 Market, By Biomarker Type, 2019 vs 2024 (USD Million)
Figure 10 Market, By Application, 2019 vs 2024 (USD Million)
Figure 11 Geographical Snapshot of the Market
Figure 12 Increasing Demand for Personalized Medicine to Drive Market Growth
Figure 13 China to Register the Highest Growth in the Market During the Forecast Period
Figure 14 APAC to Witness the Highest Growth During the Forecast Period (20192024)
Figure 15 Developing Markets to Register A Higher Growth Rate Between 2019 & 2024
Figure 16 Market: Drivers, Restraints, Opportunities, and Challenges
Figure 17 Global Cancer Incidence, 20082030
Figure 18 Launch of Personalized Medicine Products, 20082016
Figure 19 Increasing Use of Integrated Omics Data and Growing Focus on Liquid Biopsy Tests are Key Market Trends
Figure 20 Immunoassays to Dominate the Cancer/Tumor Profiling Market During the Forecast Period
Figure 21 Breast Cancer Segment to Dominate the Market During the Forecast Period
Figure 22 Global Lung Cancer Incidence, 2012-2030
Figure 23 Colorectal Cancer Incidence Rate, Key Countries (2018)
Figure 24 Genetic Biomarkers to Dominate the Market During the Forecast Period
Figure 25 Research Applications to Dominate the Market During the Forecast Period
Figure 26 Market: Geographic Snapshot (2018)
Figure 27 North America: Market Snapshot
Figure 28 Europe: Market Snapshot
Figure 29 Asia Pacific: Market Snapshot
Figure 30 Illumina, Inc.: Company Snapshot (2018)
Figure 31 Qiagen N.V.: Company Snapshot (2018)
Figure 32 Neogenomic Laboratories, Inc.: Company Snapshot (2018)
Figure 33 Sysmex Corporation: Company Snapshot (2018)
Figure 34 HTG Molecular Diagnostics, Inc.: Company Snapshot (2018)
Figure 35 Genomic Health, Inc.: Company Snapshot (2018)
Figure 36 Nanostring Technologies, Inc.: Company Snapshot (2018)
Figure 37 Guardant Health, Inc.: Company Snapshot (2018)
Figure 38 Foundation Medicine: Company Snapshot (2018)
This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.
Secondary Research
The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, companies house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of cancer/tumor profiling market. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing directors, technology & innovation directors, and related key executives from various key companies and organizations operating in cancer/tumor profiling market. Primary sources from the demand side include scientists, pathologists, doctors, and purchase managers of research institutes, government & private hospitals, biotechnology industries, and academic institutes. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends & key market dynamics.
A breakdown of the primary respondents is provided below:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The market size estimates and forecasts provided in this study are derived through a mix of the bottom-up approach (segmental analysis of major segments) and top-down approach (assessment of utilization/adoption/penetration trends, by technology, by cancer type, by biomarker type, by application, and region).
Data Triangulation
After arriving at the market size, cancer/tumor profiling market was divided into several segments and subsegments. The data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments & subsegments, wherever applicable.
Objectives of the Study
- To define, describe, segment, and forecast global cancer/tumor profiling market by technology, cancer type, biomarker type, application, and region.
- To provide detailed information about the factors influencing market growth (such as drivers, restraints, opportunities, and industry-specific challenges)
- To analyze micro-markets with respect to individual growth trends, prospects, and contributions to overall market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of market in five main regions along with their respective key countries (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa)
- To profile key players in global market and comprehensively analyze their core competencies and market shares
- To track and analyze competitive developments such as acquisitions; new product launches, enhancements and approvals; expansions; collaborations, partnerships, & agreements; and R&D activities of the leading players in market.
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the companys specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (Up to 5)
Geographic Analysis
- A further breakdown of the Latin America cancer/tumor profiling market into Brazil, Mexico, and Rest of Latin America
- A further breakdown of European market into Switzerland, Netherlands, and Rest of Europe.
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Cancer/Tumor Profiling Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Growth opportunities and latent adjacency in Cancer/Tumor Profiling Market